QBS72S for Breast Cancer

Stanford Cancer Institute, Palo Alto, CA
Breast Cancer+1 More ConditionsQBS72S - Drug
All Sexes

Study Summary

This trial will test whether a new chemotherapy agent is effective and safe in treating brain metastases from triple negative breast cancer.

Eligible Conditions
  • Breast Cancer
  • Metastatic Brain Tumors

Treatment Effectiveness

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: 6 months

2 months
Overall Survival (OS)
Progression-free Survival (PFS)
Day 30
Related Adverse Events (AEs)
6 months
Duration of Response (DoR)
Overall Response against Intracranial Tumor Lesions
Month 6
RECIST 1.1 response criteria

Trial Safety

Phase-Based Safety

2 of 3
This is further along than 68% of similar trials

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

QBS72S 12 mg/m2 IV injection
1 of 1

Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: QBS72S · No Placebo Group · Phase 2

QBS72S 12 mg/m2 IV injection
Experimental Group · 1 Intervention: QBS72S · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months

Who is running the clinical trial?

Quadriga Biosciences, Inc.Industry Sponsor
2 Previous Clinical Trials
265 Total Patients Enrolled
1 Trials studying Breast Cancer
15 Patients Enrolled for Breast Cancer
Melanie Hayden GephartLead Sponsor
Melanie H Gephart, MD, MASPrincipal InvestigatorStanford University

Eligibility Criteria

Age 18+ · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

How hazardous is QBS72S to human health?

"There is limited evidence suggesting QBS72S's safety, giving it a rating of 2. However, there are no findings to support the drug's efficacy yet." - Anonymous Online Contributor

Unverified Answer

How many participants are involved in the current clinical research?

"Yes, the information hosted on clinicaltrials.gov confirms that this medical trial is actively engaging patients; it was initially posted on August 16th 2022 and its most recent update took place October 13th of that same year. The study requires 35 participants to be sourced from a single site." - Anonymous Online Contributor

Unverified Answer

Are there any vacancies available for this clinical experiment?

"The clinical trial is currently open to applicants, as referenced on the official website. This study was initially posted in August of 2022 and underwent its most recent update earlier this month." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.